Efficacy and Safety of BAI Combined With DEB-BACE of EqualSpheres in the Treatment of Advanced NSCLC

Prior treatment

• Previously received interventional therapy (iodine particle implantation, ablation, TACE treatment);

Other illness

• Have had or currently having other primary malignant tumors;
• Patients with active infection requiring antibiotic treatment;
• Uncontrolled hypertension, diabetes, and cardiovascular disease with obvious symptoms;
• contrast agent allergy;

Lab values

• White blood cell \< 3×109/L, platelet count \< 50×109/L, HGB \< 90 g/L;
• Hepatic and renal insufficiency (creatinine \> 2 mg/L; AST and/or ALT \> 2 times the normal upper limit);
• Coagulation dysfunction (INR \> 1.5) or known bleeding disease (except lung cancer combined with hemoptysis), or anticoagulation therapy;

Other

• Combined with extensive and uncontrolled extrapulmonary metastases, such as liver metastasis, bone metastasis, and brain metastasis;
• Women with pregnancy or lactation.

• Age \> 18 years old, male and female;
• According to the Guidelines for the Diagnosis and Treatment of Primary Lung Cancer (2022 edition), the patient was diagnosed with NSCLC by imaging and histopathology;
• TNM stages were III-IV;
• Newly diagnosed, first-line treatment failure, refusal or inability to perform conventional treatment (surgery, chemoradiotherapy);
• ECOG PS ≤2;
• Expected survival \> 3 months;
• Sign the informed consent voluntarily, and the compliance is good.